Today in Europe there is a growing trend toward establishing venture-capital funds that are sourced exclusively by a major corporation. 

Some big pharmaceutical firms have recognized the potential rewards for nurturing small start-up firms—namely, novel IP—and have begun putting together modest funds of their own to pursue them. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.